- Caroline FentonAffiliated withAdis International Limited
- , Gillian M. KeatingAffiliated withAdis International Limited
- , Katherine A. Lyseng-WilliamsonAffiliated withAdis International Limited Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Moxonidine (Physiotens®, Moxon®, Cynt®) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients. Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.
Moxonidine is a centrally acting selective agonist at imidazoline I1 receptors, tor which it has an affinity >30-fold that for α2-adrenoceptors. Moxonidine inhibits peripheral sympathetic activity, which decreases peripheral vascular resistance and results in significant decreases in systolic and diastolic BP (SBP and DBP). Moxonidine has minimal effect on cardiac haemodynamics and reduces left ventricular mass. Markers of endothelial dysfunction and end-organ damage, including microalbuminuria, improved in hypertensive patients who achieved BP control with moxonidine. Moxonidine also improved the metabolic profile of patients with hypertension and type 2 diabetes or impaired glucose tolerance. Oral moxonidine is rapidly absorbed, although the maximum antihypertensive effect occurs 3–4 hours after administration.
Oral bioavailability is 88% and is unaffected by food. No first-pass metabolism occurs and moxonidine is mostly excreted unchanged in the urine.
In well designed, 8-week trials, monotherapy with moxonidine 0.2–0.6 mg/day reduced sitting DBP to a significantly greater extent than placebo (mean change from baseline −10.7 to −13.2 vs −2.3 to −9mm Hg) in patients with mild to moderate essential hypertension. Sitting SBP also improved from baseline to a significantly greater extent with moxonidine than with placebo (mean −19.5 to −24.9 vs −1.2 to −13mm Hg). Reductions in sitting SBP and DBP with moxonidine 0.2–0.8 mg/day at 8 weeks were similar to those with enalapril 5–20mg once daily, atenolol 50–100 mg/day (except in postmenopausal women where atenolol reduced BP to a greater extent than moxonidine), hydrochlorothiazide 25mg once daily and rilmenidine 1–2 mg/day. At 26 weeks, reductions in sitting SBP and DBP with moxonidine 0.2–0.4 mg/day were similar to those with nifedipine sustained release 20–40 mg/day.
Once-daily adjunctive moxonidine 0.4mg was also effective in patients with mild to moderate hypertension in well designed trials. In patients who did not respond to moxonidine monotherapy, mean improvements in sitting DBP at 4 weeks were −7.3mm Hg with moxonidine 0.4mg once daily plus amlodipine 5mg once daily, −4.8mm Hg with moxonidine 0.4mg once daily plus enalapril 10mg once daily and −3.2mm Hg with moxonidine 0.4mg once daily plus hydrochlorothiazide 12.5mg once daily. In another trial, changes in sitting SBP and DBP after 8 weeks’ treatment were significantly greater with once-daily moxonidine 0.4mg plus hydrochlorothiazide 25mg than with the respective monotherapies (−27 vs −20 and −22mm Hg and −16 vs −12 and −13mm Hg).
Moxonidine was generally well tolerated in clinical trials in patients with mild to moderate hypertension. In placebo-controlled monotherapy trials, 36–43% of moxonidine recipients experienced treatment-emergent adverse events versus 22–29% of placebo recipients and ≈32% and 35% of enalapril and hydrochlorothiazide recipients, respectively. Dry mouth was the most common adverse event with moxonidine monotherapy, affecting 11–20% of patients; other all-cause adverse events included diarrhoea, headache, bronchitis, nausea, dizziness and back pain. Other than dry mouth, asthenia and fatigue, adverse events in moxonidine monotherapy recipients were not generally related to α2-adrenoceptor inhibition. No new adverse events were reported in combination therapy trials.
Moxonidine was also well tolerated in a pooled analysis of postmarketing surveillance studies in 91 170 patients, about two-thirds of whom received moxonidine as monotherapy. Adverse events affected 9.4% of patients, causing 1.8% to discontinue treatment, and were generally not related to dosage, treatment duration, sex or age; dry mouth affected 4.2% of patients aged >65 years versus 2.7% of those aged <40 years.
Volume 66, Issue 4 , pp 477-496
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors